Evommune, Inc.
EVMN
Positions held
Your positionsEVMN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $232.63M | Enterprise value | $40.47M | Trailing P/E | — | Forward P/E | -1.81 |
| PEG | — | Price / book | 0.84 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 100.0% | Operating margin | -10.2% |
| Profit margin | 0.0% | ROE | -52.1% | ROA | -32.0% | Debt / equity | 0.03 |
| Current ratio | 11.68 | Free cash flow | -$39.13M | Analyst recommendation | buy | Mean target | $24.13 |
| 52w high | $33.20 | 52w low | $6.02 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $10.0M | — |
| Op margin | — | — | — | -133.3% | — |
| Net income | -$32.2M | -$21.7M | -$28.3M | -$12.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$34.9M | -$24.0M | -$29.7M | -$13.3M | — |
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $13.0M | — |
| Op margin | -623.6% | — |
| Net income | -$68.9M | — |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$81.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · EADV26: Key late-stage readouts from the conference
2026-09-16 · Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
2026-09-11 · Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
2026-09-09 · Sector Update: Healthcare Stocks Decline in Afternoon Trading
2026-09-09 · This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
2026-09-09 · Sector Update: Healthcare Stocks Mixed Premarket Wednesday
2026-09-09 · Evommune Halts Atopic Dermatitis Program Following Trial Failure
2026-09-09 · Evommune Atopic Dermatitis Phase 2b Trial Misses Endpoints; Shares Down Pre-Bell
2026-09-08 · Why Is EVMN Stock Down 13% After-Hours?
2026-09-08 · Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
Price (daily)
Full chart · RSI · MACD · patterns